Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

posiedon59 102 posts  |  Last Activity: 10 hours ago Member since: Jan 8, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • soon to follow, OREX will hit $25 sooner rather than later. The Shorts played their hand and have lost now they want you to fold. Short squeeze to follow. GL

    Sentiment: Strong Buy

  • Reply to

    Is mysimba good for your heart

    by idpatton01 12 hours ago
    posiedon59 posiedon59 12 hours ago Flag

    No, I suggest you take a 100 tabs and then tell us if it hurt you or not. We'll wait for you to respond.

    Sentiment: Strong Buy

  • Ignore the monkey chatter, totally ignore Crapper and the Street defecants, and let NWBO medical results speak for themselves. Big Pharma is scared witless. They understand that DCVAX will essentially render Chemo unnecessary and obsolete. That is the big THREAT to an established $$$$Trillion dollar industry. You have to see the forest, and STOP looking at the trees and the "stumps". There's a reason for the push back, you just have to be smart enough to figure it out. GL

    Sentiment: Strong Buy

  • As soon as the market opens, NWBO is up by at least .10 to .25, within minutes, the price is pushed down. So either you have traders selling and buying as quickly as possible, or you have a concerted effort to push NWBO down through naked shorting anytime there is good news. How many billions of $$$$$ each day are traders losing to these naked shorts who are essentially stealing from your pockets. Shorting stocks they haven't borrowed and then constantly pushing the stock down anytime there is good news. Timing their shorts to occur anytime good news is released. The SEC asleep at the wheel or turning a blind eye. This really is just government sanctioned criminal activity.

    Sentiment: Strong Buy

  • posiedon59 by posiedon59 Mar 25, 2015 8:57 AM Flag

    Soooooo funny! They are all so utterly ridiculous. Have a good laugh.

    Sentiment: Strong Buy

  • Cover Shorts. You guys are going to be in a lot of pain. Thousand of dollars in the hole with no way out. Short squeeze. Silly Wabbits never learn.

    Sentiment: Strong Buy

  • Can someone who watched put the key talking points out on the board. Thanks.

    Sentiment: Strong Buy

  • Reply to

    OREX Facts

    by icoltsi18 Mar 24, 2015 8:34 AM
    posiedon59 posiedon59 Mar 24, 2015 8:59 AM Flag

    Fact: You are Short
    Fact: You are manipulative
    Fact: You need to cover before your losses on this stock put you out on the sidewalk with your wife and kids.

    Sentiment: Strong Buy

  • Desperation is a unique human emotion. Some people are willing to say or do anything to save themselves from grievous errors in judgement, while others will take the high road, admitting their foolish mistakes and learning not to make the same mistake over again. Shorts on this board, idpattoen, bababara and hellbent, are just cowards and lowlifes who see their short positions going deeper into the red and they will say anything to keep from losing more. They can't bring themselves to cover and they can't stop posting. It is really quite pathetic and sad.

    Sentiment: Strong Buy

  • Reply to

    FIFTEEN (15) Law Firms on OREX's heels...

    by bruce_longshank Mar 23, 2015 6:42 AM
    posiedon59 posiedon59 Mar 23, 2015 4:00 PM Flag

    The effect of 15 law firms on OREX share price has been nil. Tells you more about the character of these law firms.

    Sentiment: Strong Buy

  • In the U.S., advisory committees made up of outside experts make approval recommendations to the FDA, but the agency has the final say. There are many examples of companies getting positive recommendations from committees only to be rejected by the FDA, including Orexigen's first attempt at an approval in the U.S.

    In the EU, the situation is completely different. Technically, the CHMP makes "recommendations" to the EC, but the CHMP is more akin to the FDA than a committee of outside experts. In fact, the people voting on the CHMP recommendations are regulators from each of the member states.

    I only know of two cases where the CHMP made a positive recommendation and the EC didn't eventually approve. Both had extenuating circumstances.

    After Johnson & Johnson's Zeftera was given a positive recommendation by the CHMP in 2008, the committee learned that the FDA was concerned about the study sites that performed the clinical trial used to support the approval. The committee eventually determined that the trial results may not be reliable because the study wasn't performed under "good clinical practice" at some of the sites, and it eventually reneged its positive recommendation.

    Last year, Merck and Endocyte got a positive opinion from the CHMP for their cancer drug vintafolide based on phase 2 data, but two months later, the duo stopped the phase 3 confirmation trial early because patients getting the drug weren't doing any better than those who got a placebo. The companies subsequently withdrew the EU marketing application.

    EU important for Orexigen
    The request for a meeting to review Mysimba seems more political than anything else. Last month, a coalition of European consumer groups called the European Bureau of Consumer Unions wrote to the EC asking the commission to not approve Mysimba. Prescrire, a non-profit continuing education organization, also complained about the approval.

    While the meeting vote introduces some uncertainty to the eventual approval, it st

    Sentiment: Strong Buy

  • Pathetic losers.

    Sentiment: Strong Buy

  • Orex for an easy payday.

    When Charles Foti was Sheriff, he illegally strip searched 80,000 people.[15] Even mothers trying to get their children to school.[16] When the Federal Appeals Court told Foti to stop, he refused to listen.[17] Because of this, Foti cost taxpayers 10 million dollars.[15] When he was the Attorney General for the State of Louisiana, he delayed suing insurance companies.[18] Foti also had Dr. Anna Pou and two nurses arrested and tried to prosecute Dr. Anna Pou when she is considered a "Katrina Hero."[19]

    Sentiment: Strong Buy

  • Reply to

    When?

    by aussieaye Mar 23, 2015 9:58 AM
    posiedon59 posiedon59 Mar 23, 2015 11:12 AM Flag

    This is their game! Fear, Falsehoods and Frustration is what they gamble on. I don't hate the Shorts because they don't really matter. You just need to decide what kind of investor you are....panic driven or DD driven.

    Sentiment: Strong Buy

  • With marketing approval of Mysimba in the EU, this should double the share price of OREX. Throw in a short squeeze and that pushes us to $20 or beyond. Think about, OREX has stayed above $7 regardless of the number of "SEC filings " and "investigations, really no effect. If Contrave heart benefits are validated, IMO they already have been, we may see $30+ A diet pill for diabetes 2, weight loss, weight maintenance and cardio-related benefits that may prevent heart attacks....do the math.

    Sentiment: Strong Buy

  • In October 2013, we submitted a marketing authorization application for Contrave, under the name Mysimba, to the European Medicines Agency, or EMA. This submission is being reviewed by the EMA's Committee for Medicinal Products for Human Use, or CHMP, for the first time. In December 2014, the CHMP adopted a positive opinion recommending the European Commission, or EC, grant a centralized marketing authorization, or CMA, for Mysimba. The CHMP recently released minutes from their December meeting stating that the positive opinion for Mysimba was adopted by a majority vote with 31 members in favor and two opposed. Procedurally, a positive opinion and recommendation of the CHMP is then referred to the EC's Standing Committee for Medicinal Products, or Standing Committee, which is composed of representatives from each member state of the E.U. In a process that occurs either through a written procedure or in a meeting, the Standing Committee reviews the draft EC decision to grant marketing authorization. Draft decisions are adopted by majority vote. The EC recently informed us that at the request of one member state, the draft EC decision granting marketing authorization for Mysimba will be reviewed during a meeting of the Standing Committee being held in March 2015. A positive decision by the Standing Committee would allow Mysimba to be placed on the market in all 28 E.U. member states, as well as Iceland, Liechtenstein and Norway.

    Sentiment: Strong Buy

  • Time to iggy this guy out.

    Sentiment: Strong Buy

  • posiedon59 by posiedon59 Mar 22, 2015 1:13 PM Flag

    Who knows, better yet who cares. Now be a good short, and go take your meds. Be careful not to mix them up and read the labels. LOL

    Sentiment: Strong Buy

  • Wells Fargo analyst Matthew Andrews predicts Contrave will bring in $634 million in sales in 2020, but has forecast that figure could be as high as $1.2 billion if Orexigen wins approval for the drug in treating diabetes.

    Sentiment: Strong Buy

  • Unlike Bupropin alone, Contrave DID NOT have any occurrence of patients experiencing suicidal thoughts. The combination of the two drugs is self-cancelling. Barking up the wrong tree. Once again, the truth is out there. CHMP approved Contrave/Mysimba without any black box warning.

    Like any drug, Contrave can cause unwanted side effects. These include
    •nausea and vomiting
    •constipation
    •headache
    •dizziness
    •insomnia
    •dry mouth
    •diarrhea
    •elevated blood pressure and heart rate
    •seizures

    Since the use of bupropion has been linked to the onset of suicidal thoughts, Contrave will carry the same black-box warning about this that bupropion does.

    Sentiment: Strong Buy

ARNA
4.34-0.02(-0.46%)Mar 26 4:00 PMEDT